Comparative Pharmacology
Head-to-head clinical analysis: ESTROSTEP FE versus NORDETTE 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTROSTEP FE versus NORDETTE 21.
ESTROSTEP FE vs NORDETTE-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to prevent sperm penetration, and alters endometrial lining to reduce implantation likelihood.
One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).
One tablet (0.15 mg levonorgestrel, 0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours. Clinical context: Steady-state reached within 7-10 days.
Ethinylestradiol: 13 ± 7 hours (terminal), clinically relevant for once-daily dosing; Levonorgestrel: 24 ± 6 hours (terminal), supporting steady-state after ~5 days
Renal: ~40% as metabolites; fecal: ~30% (biliary); remainder as conjugates.
Renal: ~50% (as glucuronide and sulfate conjugates); Fecal: ~40% (enterohepatic recirculation); Biliary: <10%
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive